SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion. GLP-1 (glucagon-like ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

A guideline has recommended two key drugs be prescribed in all patients with type 2 diabetes who are at higher risk.

In 2025, Släcka introduces a functional beverage designed to combat mid-afternoon cravings by offering a healthier ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Weight-loss drugs like Mounjaro and Ozempic work wonders on your waistline but can cause chaos with your scalp. Here’s what ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...